New Anticoagulant Savaysa Is Now Available

Roni Shye
Roni Shye, PharmD BCGP BCACP, is a licensed pharmacist in the states of Florida, Ohio, and Pennsylvania.
Posted on

Savaysa (edoxaban) is an anti-clotting medication indicated for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and nonvalvular atrial fibrillation (NVAF). It was approved by the FDA on January 8, 2015, and is now available in pharmacies.

What are deep vein thrombosis, pulmonary embolism, and nonvalvular atrial fibrillation?

Deep vein thrombosis is a blood clot that can occur in a deep vein such as those of the thigh.

A pulmonary embolism is a blood clot that breaks away from its original location such as the thigh and travels to the lung where it can block blood flow.

Nonvalvular atrial fibrillation is an abnormal heart rhythm that is not caused by a heart valve problem.

What type of medication is Savaysa and how does it work?
Savaysa is part of the class of anticoagulant medications known as Factor Xa inhibitors. Factor Xa inhibitors stop a clot from forming by affecting a specific part of the clotting process.

Are there any other medications similar to Savaysa?

Yes. Some other Factor Xa inhibitor anticoagulants include Eliquis (apixaban), Xarelto (rivaroxaban), and Arixtra (fondaparinux).

In what dosage forms and strengths is Savaysa available?
Savaysa is available as a tablet in 15, 30, and 60 mg dosages.

How is Savaysa used?
Savaysa is to be administered ONCE DAILY with or without food.

What are some side effects of Savaysa?

The most common side effects associated with Savaysa are bleeding and anemia.

Want more information?

Check out the manufacturer website here.

And see the FDA approval statement here.

Drugs featured in this story

Filed under